BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22659450)

  • 1. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
    Jun HJ; Johnson H; Bronson RT; de Feraudy S; White F; Charest A
    Cancer Res; 2012 Aug; 72(15):3764-74. PubMed ID: 22659450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
    Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
    Ren S; Huang S; Ye X; Feng L; Lu Y; Zhou C; Zhao J; He T; Wang J; Li B
    Cancer Treat Res Commun; 2021; 27():100377. PubMed ID: 33945921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
    Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
    Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD74-NRG1 fusions in lung adenocarcinoma.
    Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
    Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 10. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
    Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
    FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS kinase fusions are not common in Chinese patients with cholangiocarcinoma.
    Liu P; Wu Y; Sun L; Zuo Q; Shi M
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Apr; 33(4):474-8. PubMed ID: 23644102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
    Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
    Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
    Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
    Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity.
    Ogura H; Nagatake-Kobayashi Y; Adachi J; Tomonaga T; Fujita N; Katayama R
    Sci Rep; 2017 Jul; 7(1):5519. PubMed ID: 28717217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
    Neel DS; Allegakoen DV; Olivas V; Mayekar MK; Hemmati G; Chatterjee N; Blakely CM; McCoach CE; Rotow JK; Le A; Karachaliou N; Rosell R; Riess JW; Nichols R; Doebele RC; Bivona TG
    Cancer Res; 2019 Feb; 79(3):546-556. PubMed ID: 30538120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex.
    Shi X; Leng L; Wang T; Wang W; Du X; Li J; McDonald C; Chen Z; Murphy JW; Lolis E; Noble P; Knudson W; Bucala R
    Immunity; 2006 Oct; 25(4):595-606. PubMed ID: 17045821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.